NfL is an attractive biomarker for use in clinical trials of neurodegenerative diseases, including ALS, as some researchers suggest treatments not protective against increases in NfL lack the potential to modify disease (Kiernan et al., 2021). Here, NEFL is linked to neurodegenerative disease.